posted on 2023-04-17, 16:39authored byDalton
R. Kim, Meghan J. Orr, Ada J. Kwong, Kristine K. Deibler, Hasan H. Munshi, Cory Seth Bridges, Taylor Jie Chen, Xiaoyu Zhang, H. Daniel Lacorazza, Karl A. Scheidt
The mitogen-activated protein kinase signaling cascade
is conserved
across eukaryotes, where it plays a critical role in the regulation
of activities including proliferation, differentiation, and stress
responses. This pathway propagates external stimuli through a series
of phosphorylation events, which allows external signals to influence
metabolic and transcriptional activities. Within the cascade, MEK,
or MAP2K, enzymes occupy a molecular crossroads immediately upstream
to significant signal divergence and cross-talk. One such kinase,
MAP2K7, also known as MEK7 and MKK7, is a protein of great interest
in the molecular pathophysiology underlying pediatric T cell acute
lymphoblastic leukemia (T-ALL). Herein, we describe the rational design,
synthesis, evaluation, and optimization of a novel class of irreversible
MAP2K7 inhibitors. With a streamlined one-pot synthesis, favorable in vitro potency and selectivity, and promising cellular
activity, this novel class of compounds wields promise as a powerful
tool in the study of pediatric T-ALL.